Amanda E Calvert

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6337289/publications.pdf

Version: 2024-02-01

24 papers 651 citations

623574 14 h-index 610775 24 g-index

24 all docs

24 docs citations

times ranked

24

1292 citing authors

#	Article	IF	CITATIONS
1	Rapid colorimetric detection of Zika virus from serum and urine specimens by reverse transcription loop-mediated isothermal amplification (RT-LAMP). PLoS ONE, 2017, 12, e0185340.	1.1	85
2	The dengue virus type 2 envelope protein fusion peptide is essential for membrane fusion. Virology, 2010, 396, 305-315.	1.1	69
3	Glycosylation of the dengue 2 virus E protein at N67 is critical for virus growth in vitro but not for growth in intrathoracically inoculated Aedes aegypti mosquitoes. Virology, 2007, 366, 415-423.	1.1	57
4	Molecular, serological and in vitro culture-based characterization of Bourbon virus, a newly described human pathogen of the genus Thogotovirus. Journal of Clinical Virology, 2015, 73, 127-132.	1.6	53
5	Amino acid changes within the E protein hinge region that affect dengue virus type 2 infectivity and fusion. Virology, 2011, 413, 118-127.	1.1	42
6	Domain-III FG loop of the dengue virus type 2 envelope protein is important for infection of mammalian cells and Aedes aegypti mosquitoes. Virology, 2010, 406, 328-335.	1.1	41
7	Mutation of the dengue virus type 2 envelope protein heparan sulfate binding sites or the domain III lateral ridge blocks replication in Vero cells prior to membrane fusion. Virology, 2013, 441, 114-125.	1.1	41
8	Non-structural proteins of dengue 2 virus offer limited protection to interferon-deficient mice after dengue 2 virus challenge. Journal of General Virology, 2006, 87, 339-346.	1.3	36
9	Ability To Serologically Confirm Recent Zika Virus Infection in Areas with Varying Past Incidence of Dengue Virus Infection in the United States and U.S. Territories in 2016. Journal of Clinical Microbiology, 2018, 56, .	1.8	36
10	Vertebrate Host Susceptibility to Heartland Virus. Emerging Infectious Diseases, 2016, 22, 2070-2077.	2.0	34
11	Patterns in Zika Virus Testing and Infection, by Report of Symptoms and Pregnancy Status — United States, January 3–March 5, 2016. Morbidity and Mortality Weekly Report, 2016, 65, 395-399.	9.0	29
12	Development of a small animal peripheral challenge model of Japanese encephalitis virus using interferon deficient AG129 mice and the SA14-14-2 vaccine virus strain. Vaccine, 2014, 32, 258-264.	1.7	21
13	Human monoclonal antibodies to West Nile virus identify epitopes on the prM protein. Virology, 2011, 410, 30-37.	1.1	17
14	Development and Characterization of Monoclonal Antibodies Directed Against the Nucleoprotein of Heartland Virus. American Journal of Tropical Medicine and Hygiene, 2015, 93, 1338-1340.	0.6	17
15	Mutations in the West Nile prM protein affect VLP and virion secretion in vitro. Virology, 2012, 433, 35-44.	1.1	14
16	Exposures Before Issuance of Stay-at-Home Orders Among Persons with Laboratory-Confirmed COVID-19 — Colorado, March 2020. Morbidity and Mortality Weekly Report, 2020, 69, 847-849.	9.0	14
17	Incorporation of IgG Depletion in a Neutralization Assay Facilitates Differential Diagnosis of Zika and Dengue in Secondary Flavivirus Infection Cases. Journal of Clinical Microbiology, 2018, 56, .	1.8	13
18	A humanized monoclonal antibody neutralizes yellow fever virus strain 17D-204 inÂvitro but does not protect a mouse model from disease. Antiviral Research, 2016, 131, 92-99.	1.9	8

#	Article	IF	CITATIONS
19	The Specificity of the Persistent IgM Neutralizing Antibody Response in Zika Virus Infections among Individuals with Prior Dengue Virus Exposure. Journal of Clinical Microbiology, 2021, 59, e0040021.	1.8	6
20	Development of diagnostic microsphere-based immunoassays for Heartland virus. Journal of Clinical Virology, 2021, 134, 104693.	1.6	5
21	A Monoclonal Antibody Specific for Japanese Encephalitis Virus with High Neutralizing Capability for Inclusion as a Positive Control in Diagnostic Neutralization Tests. American Journal of Tropical Medicine and Hygiene, 2019, 101, 233-236.	0.6	5
22	Exposing cryptic epitopes on the Venezuelan equine encephalitis virus E1 glycoprotein prior to treatment with alphavirus cross-reactive monoclonal antibody allows blockage of replication early in infection. Virology, 2022, 565, 13-21.	1.1	3
23	Monoclonal antibodies to Cache Valley virus for serological diagnosis. PLoS Neglected Tropical Diseases, 2022, 16, e0010156.	1.3	3
24	Development of HEK-293 Cell Lines Constitutively Expressing Flaviviral Antigens for Use in Diagnostics. Microbiology Spectrum, 2022, 10, e0059222.	1.2	2